Product
Secukinumab/Adalimumab-Biosimilar
1 clinical trial
1 indication
Indication
Axial SpondyloarthritisClinical trial
A Randomized, Open Label Multicenter Trial to Investigate the Efficacy of a Treat-to-target (T2T) Treatment Strategy With Secukinumab (AIN457) as a First-line Biologic Compared to a Standard-of-care (SOC) Treatment Over 36 Weeks in Patients With Active Axial Spondyloarthritis (axSpA)Status: Completed, Estimated PCD: 2022-02-04